clinical trial · NCT06144606
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 60
B-Cell Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaTecartus
brief summary
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
started
Dec 26, 2023
primary completion
Nov 15, 2028
completion
Nov 15, 2028
last updated
Mar 31, 2026
official title
Phase 2 Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol